Charles River Laboratories International (CRL) Net Income towards Common Stockholders (2009 - 2025)

Charles River Laboratories International's Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$276.6 million for Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders fell 28.21% year-over-year to -$276.6 million; the TTM figure through Dec 2025 stood at -$144.3 million (down 1501.75% YoY), while the FY2025 annual figure was -$144.3 million, down 1501.75% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$276.6 million, down from $54.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $189.1 million in Q4 2022, with the low at -$276.6 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is $90.0 million (2021), against an average of $61.6 million.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders jumped 48.94% in 2022, then sank 215.3% in 2024.
• Charles River Laboratories International's Net Income towards Common Stockholders stood at $139.8 million in 2021, then jumped by 35.24% to $189.1 million in 2022, then declined by 1.07% to $187.1 million in 2023, then tumbled by 215.3% to -$215.7 million in 2024, then decreased by 28.21% to -$276.6 million in 2025.
• Business Quant data shows CRL's Net Income towards Common Stockholders at -$276.6 million in Q4 2025, $54.4 million in Q3 2025, and $52.3 million in Q2 2025.